AIM ImmunoTech Shares Slide Despite Clinical Progress and Patent Victory

AIM ImmunoTech continues to experience significant downward pressure on its stock value, even as the company achieves critical milestones in its clinical development program and secures a major patent victory in Japan. This divergence highlights a growing disconnect between the biotechnology firm’s operational progress and its market performance, with investors maintaining a cautious stance despite expanding intellectual property rights.

The equity faced another challenging session, closing at $2.52 on Friday after opening at $2.61, representing a decline of 3.45%. Throughout the trading day, shares fluctuated between $2.66 and $2.49. The downward movement persisted into Saturday morning, with the stock trading at $2.49, reflecting a 24-hour decrease of 4.96%.

Friday’s trading volume reached 60,381 shares. Over a broader timeframe, the security has declined in six of... Read more...